EGFR inhibitors
BlossomHill Therapeutics Begins Trial of BH-30643 in EGFR-, HER2-Mutant NSCLC
BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.
NICE Recommends NHS England Provide AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC
The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.
Dizal Pharmaceutical Seeking FDA Approval for Sunvozertinib in EGFR Exon 20 Insertion-Mutated NSCLC
Chinese regulators approved the drug for the same subset of advanced, previously treated EGFR-mutated NSCLC patients in 2023.
European Commission Approves Rybrevant, Lazcluze in EGFR-Mutated NSCLC
Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.
European Commission Approves AstraZeneca's Tagrisso in Unresectable EGFR-Mutated NSCLC
Tagrisso is the first targeted therapy for European patients with unresectable EGFR-mutated lung cancer.
Oct 24, 2023